other material
confidence high
sentiment positive
materiality 0.80
Viking Therapeutics Reports Positive Phase 1 Results for Oral VK2735 with Up to 5.3% Weight Loss
Viking Therapeutics, Inc.
- Up to 5.3% mean weight loss from baseline after 28 days in Phase 1 MAD trial of oral VK2735
- Placebo-adjusted mean weight loss up to 3.3%; up to 57% of treated subjects achieved ≥5% weight loss vs 0% placebo
- VK2735 well-tolerated with low GI adverse events; no serious adverse events reported
- Company plans Phase 2 trial in obesity for second half of 2024